Meeting
2020 ASCO Virtual Scientific Program
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
Authors
Sherene Loi
Peter MacCallum Cancer Institute, Melbourne, VIC, Australia
Sherene Loi , Heather L. McArthur , Nadia Harbeck , Lajos Pusztai , Suzette Delaloge , Kristen Letrent , Tian Chen , Bin Li , Kay Tatsuoka , Dimitrios Zardavas , Giuseppe Curigliano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04109066
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS604)
DOI
10.1200/JCO.2020.38.15_suppl.TPS604
Abstract #
TPS604
Poster Bd #
96
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
First Author: Maryann J. Kwa
Poster
2021 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.
First Author: Shigehira Saji
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
First Author: Sara M. Tolaney
Poster
2020 ASCO Virtual Scientific Program
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde